Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874) Cyclically Adjusted Revenue per Share: HK$27.47 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00874 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd HKSE:00874
88 GF Score
Price HK$13.31
GF Value HK$19.01
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Cyclically Adjusted Revenue per Share?

Guangzhou Baiyunshan Pharmaceutical Holdings Co HKSE:00874 -0.89% 88 Cyclically Adjusted Revenue per Share is HK$27.47 as of Jun. 2026. GuruFocus rates HKSE:00874 with a GF Score™ of 88/100 and a GF Value™ of HK$19.01 (Significantly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's adjusted revenue per share for the three months ended in Jun. 2026 was HK$13.384. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is HK$27.47 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Guangzhou Baiyunshan Pharmaceutical Holdings Co's average Cyclically Adjusted Revenue Growth Rate was 9.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 14.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Guangzhou Baiyunshan Pharmaceutical Holdings Co was 23.00% per year. The lowest was -0.80% per year. And the median was 10.00% per year.

As of today (2026-09-12), Guangzhou Baiyunshan Pharmaceutical Holdings Co's current stock price is HK$13.31. Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was HK$27.47. Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted PS Ratio of today is 0.48.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Guangzhou Baiyunshan Pharmaceutical Holdings Co was 3.78. The lowest was 0.51. And the median was 1.33.


Guangzhou Baiyunshan Pharmaceutical Holdings Co  (HKSE:00874) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=13.31/27.47
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Guangzhou Baiyunshan Pharmaceutical Holdings Co was 3.78. The lowest was 0.51. And the median was 1.33.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Guangzhou Baiyunshan Pharmaceutical Holdings Co Cyclically Adjusted Revenue per Share Related Terms


Guangzhou Baiyunshan Pharmaceutical Holdings Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Cyclically Adjusted Revenue per Share Chart

Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.89 21.49 23.39 21.54 25.57

Guangzhou Baiyunshan Pharmaceutical Holdings Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.31 25.87 25.57 27.98 27.47

HKSE:00874 vs MCK, COR, CAH: Cyclically Adjusted Revenue per Share Comparison

For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangzhou Baiyunshan Pharmaceutical Holdings Co Cyclically Adjusted PS Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted PS Ratio falls into.


HKSE:00874
88GF Score
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd HKSE:00874
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Baiyunshan Pharmaceutical Holdings Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Guangzhou Baiyunshan Pharmaceutical Holdings Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=13.384/116.0564*116.0564
=13.384

Current CPI (Jun. 2026) = 116.0564.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 4.124 102.400 4.674
201612 3.053 102.600 3.453
201703 3.663 103.200 4.119
201706 4.104 103.100 4.620
201709 3.524 104.100 3.929
201712 3.680 104.500 4.087
201803 5.277 105.300 5.816
201806 5.919 104.900 6.549
201809 10.582 106.600 11.521
201812 8.632 106.500 9.407
201903 12.982 107.700 13.989
201906 10.672 107.700 11.500
201909 11.587 109.800 12.247
201912 10.188 111.200 10.633
202003 11.552 112.300 11.938
202006 9.077 110.400 9.542
202009 11.502 111.700 11.951
202012 10.772 111.500 11.212
202103 14.705 112.662 15.148
202106 11.947 111.769 12.405
202109 12.909 112.215 13.351
202112 11.654 113.108 11.958
202203 15.582 114.335 15.817
202206 12.023 114.558 12.180
202209 12.096 115.339 12.171
202212 10.983 115.116 11.073
202303 15.153 115.116 15.277
202306 12.337 114.558 12.498
202309 12.021 115.339 12.096
202312 11.666 114.781 11.796
202403 15.327 115.227 15.437
202406 11.984 114.781 12.117
202409 12.204 115.785 12.233
202412 10.463 114.893 10.569
202503 14.818 115.116 14.939
202506 13.026 114.907 13.156
202509 13.284 115.471 13.351
202512 10.906 115.832 10.927
202603 16.257 116.303 16.222
202606 13.384 116.056 13.384

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of HK$27.47 mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874) has a Cyclically Adjusted Revenue per Share of HK$27.47 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted Revenue per Share too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Cyclically Adjusted Revenue per Share is HK$27.47. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted Revenue per Share compare to MCK and COR?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted Revenue per Share of HK$27.47 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Distribution company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Distribution industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Cyclically Adjusted Revenue per Share is HK$27.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$19.01, compared to a current price of HK$13.31 — trading 30% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is HK$27.47. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874), the current Cyclically Adjusted Revenue per Share is HK$27.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874) Overvalued in 2026?

Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of HK$13.31 is trading 30% below its estimated GF Value™ of HK$19.01. GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.

Key valuation signals for HKSE:00874:

  • Cyclically Adjusted Revenue per Share: HK$27.47
  • GF Value™: HK$19.01 vs. price of HK$13.31 (30% below fair value)
  • GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the HKSE:00874 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description

Other Exchanges GU5:Germany600332:China
Address 45 Sha Mian North Street, Liwan District, Guangdong Province, Guangzhou, CHN, 510130
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
88GF Score

Get the complete analysis for HKSE:00874

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$13.31
Price
HK$19.01
GF Value